Zydus Cadila gets USFDA nod for overactive bladder treatment drug

Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Solifenacin Succinate tablets, used for treatment of overactive bladder.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Solifenacin Succinate tablets, in the strengths of 5 mg and 10 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.

Solifenacin Succinate is a symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

The company said the newly-approved medication will be manufactured at the group’s formulation manufacturing facility at the special economic zone, Ahmedabad.

The group now has 309 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.

Shares of Cadila Healthcare were trading 0.01 per cent higher at Rs 422.55 on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor